Image

    Identification of the Sulfotransferase Iso-Enzyme Primarily Responsible for the Bio-Activation of Topical Minoxidil

    August 2019 in “ PubMed ”
    James McCoy, Andy Goren, Ty Naccarato … Torello Lotti
    Studysummary This abstract reports that topical minoxidil is currently the only FDA-approved treatment for pattern hair loss in both men and women.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on pubmed.ncbi.nlm.nih.gov →
    Discuss this study in the Community →

    Related research 9

    1. Sulfotransferase Activity in Plucked Hair Follicles Predicts Response to Topical Minoxidil Treatment in Brazilian Female Pattern Hair Loss Patients Dermatologic Therapy · 2019
    2. Identification of the Sulfotransferase Iso-Enzyme Primarily Responsible for the Bio-Activation of Topical Minoxidil PubMed · 2019
    3. Efficacy of Topical Latanoprost Versus Minoxidil and Betamethasone Valerate on the Treatment of Alopecia Areata Journal of Dermatological Treatment · 2017
    4. Androgenetic Alopecia and Its Remedies: A Review Journal of drug discovery and therapeutics · 2014
    5. Possibilities And Limitations For Reversal Of Age-Related Hair Loss 2010
    6. Alopecia Secondary to Mesotherapy Journal of the American Academy of Dermatology · 2009
    7. A Quantitative Hair Growth Assessment in Androgenetic Alopecia After Application of Two Cosmetic Lotions Versus 2% Topical Minoxidil Journal of The American Academy of Dermatology · 2005
    8. Comparable Efficacy of 2% Minoxidil Gel and Solution Formulations in the Treatment of Male Pattern Alopecia Journal of the American Academy of Dermatology · 1988
    9. Topical Minoxidil in Male Pattern Baldness: Effects of Discontinuation of Treatment Journal of The American Academy of Dermatology · 1987